New progress in slowing Alzheimer’s disease

Solanezumab drug shows consisting health results in new clinical trial Research about a new drug that can slow down the progression of Alzheimer’s disease suggested that disease progression rate can be cut down by a third. Pharmaceutical company Eli Lilly presented Solanezumab drug data at this year’s Alzheimer’s Association International Conference in Washington, D.C. The […]

Read More